{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-034900","form_type":"8-K","ticker":"OMER","cik":"0001285819","company_name":"OMEROS CORP","filed_at":"2024-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.971783+00:00","generated_at":"2026-05-30T00:49:48.270353+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Omeros Q3 net loss $32.2M; narsoplimab BLA resubmission path cleared after FDA meeting","bullets":["Net loss Q3 2024: $32.2M ($0.56/sh) vs $37.8M ($0.60/sh) in Q3 2023; nine-month loss $125.5M.","Cash and investments $123.2M at Sept 30, down $48.7M from Dec 31, 2023, including $18.4M narsoplimab drug substance charge and $21.2M debt repurchase.","Narsoplimab in TA-TMA: FDA presubmission in Sep 2024; minor feedback on statistical plan incorporated; BLA resubmission planned after efficacy analysis; European MAA in H1 2025.","Zaltenibart (OMS906): FDA and EU regulators agree on Phase 3 design for PNH; enrollment expected early 2025; rare pediatric disease designation for C3G.","OMIDRIA royalties $9.3M on Rayner’s U.S. sales $31.0M in Q3 2024 vs $10.0M on $33.3M in Q3 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-034900","json":"https://secwatch.observer/filing/0001437749-24-034900.json","markdown":"https://secwatch.observer/filing/0001437749-24-034900.md","text":"https://secwatch.observer/filing/0001437749-24-034900.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1285819/000143774924034900/0001437749-24-034900-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1285819/000143774924034900/omer20240808_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:49:48.270353+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}